A61P 19 - Drugs for skeletal disorders

Patents for A61P 19 - Drugs for skeletal disorders (81,981)
11/2002
11/28/2002	WO2002070563A3 Nuclear hormone receptor ligand binding domain
11/28/2002	WO2002044153A8 4-6-diphenyl pyridine derivatives as antiinflammatory agents
11/28/2002	WO2002035235A3 Net as regulator of angiogenic expression
11/28/2002	WO2002024924A3 Protein phosphatases
11/28/2002	WO2002008255A3 Cell cycle proteins and mitosis-associated molecules
11/28/2002	WO2002000648A1 Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
11/28/2002	WO2001081415A3 Parathyroid hormone and parathyroid hormone-related protein antagonists
11/28/2002	WO2001018021A9 B7-like polynucleotides, polypeptides, and antibodies
11/28/2002	US20020177717 Compounds and methods for the inhibition of the expression of VCAM-1
11/28/2002	US20020177706 Rheumatic diseases; antiarthritic agents; antitumor agents
11/28/2002	US20020177626 Comprises analgesics such as ibuprofen and diphenhydramine; storage stability
11/28/2002	US20020177618 ERK (extracellular signal regulated kinase) inhibitors for treatment of cancer, inflammatory disorders, restenosis, and cardiovascular disease
11/28/2002	US20020177605 3-substituted isoquinolin-1-yl derivatives
11/28/2002	US20020177600 Two or more ligand moieties covalently linked together by one or more linking groups enabling binding to multiple binding sites; increased efficacy, selectivity and duration; anti-proliferative and anticarcinogenic
11/28/2002	US20020177586 Method for treating fibrotic diseases or other indications ID
11/28/2002	US20020177213 Tissue plasminogen activator-like protease
11/28/2002	US20020176902 Synergistic proteoglycan compositions for treatment of inflammatory diseases
11/28/2002	US20020176887 Methods of delivery of cetyl myristoleate
11/28/2002	US20020176860 A polypeptide providing cytotoxicity, being fused to an apoptin rendering the fusion protein functionally available in aberrant cells and not functionally available in non-aberrant cells
11/28/2002	US20020176847 Administering to a mammal viral vectors for treating and preventing atherosclerosis, osteoporosis, cardiovascular disease, Alzheimer's disease, diabetes mellitus, infectious diseases, cancer, and inherited disorders
11/28/2002	DE10212572A1 Bone formation controlling composition, especially for treatment of osteoporosis, containing ANK-pyrophosphate channel modulator, e.g. human ANK gene variant or probenecid
11/28/2002	CA2448045A1 Identifying parasitic fungi of the organism, and treatment thereof
11/28/2002	CA2448022A1 Compositions for protein delivery via the pulmonary route
11/28/2002	CA2447940A1 Urazole compounds useful as anti-inflammatory agents
11/28/2002	CA2447619A1 A composition for accelerating bone fracture healing
11/28/2002	CA2447618A1 A composition for regenerative treatment of cartilage disease
11/28/2002	CA2447313A1 Monoclonal antibody neutralising cathepsin b activity and uses thereof
11/28/2002	CA2447103A1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
11/28/2002	CA2447020A1 The use of 4-aminopyridine derivatives for the treatment of mglur5 receptor mediated diseases
11/28/2002	CA2446801A1 Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
11/28/2002	CA2446734A1 Antibodies against tumor necrosis factor delta (april)
11/28/2002	CA2446331A1 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002	CA2446324A1 Quinoline derivatives as ligands for the neuropeptide y receptor
11/28/2002	CA2446313A1 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002	CA2446155A1 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
11/28/2002	CA2446154A1 4-(penyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
11/28/2002	CA2446049A1 The use of a gatran for the manufacture of a medicament for the treatment of pulmonary fibrosis
11/28/2002	CA2445631A1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002	CA2444955A1 Inactivation of genes of the mep pathway
11/28/2002	CA2444787A1 Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
11/28/2002	CA2427619A1 Pharmaceutically active isoindoline derivatives
11/28/2002	CA2410391A1 Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
11/27/2002	EP1260587A2 Tyrosyl tRNA synthetase
11/27/2002	EP1260519A1 Membrane receptors for steroids and sterols
11/27/2002	EP1260229A2 Anti-autoimmune composition comprising inhibitors of growth hormone-releasing factor activity
11/27/2002	EP1260227A1 Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
11/27/2002	EP1259626A2 Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins and screening methods for modulators
11/27/2002	EP1259616A2 Tnf-alpha variants for the treatment of tnf-alpha related disorders
11/27/2002	EP1259614A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/27/2002	EP1259612A2 G-protein coupled receptor related polypeptides
11/27/2002	EP1259611A2 G-protein coupled receptors
11/27/2002	EP1259598A2 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
11/27/2002	EP1259595A2 Integrin antagonists
11/27/2002	EP1259544A2 Heterologous polypeptide of the tnf family
11/27/2002	EP1259527A1 35 human secreted proteins
11/27/2002	EP1259520A2 Novel purines
11/27/2002	EP1259515A2 Thienopyridine derivatives and their use as anti-inflammatory agents
11/27/2002	EP1259512A1 Pteridine compounds for the treatment of psoriasis
11/27/2002	EP1259508A1 Novel biarylcarboxamides
11/27/2002	EP1259506A1 Pyrazinone thrombin inhibitors
11/27/2002	EP1259504A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents
11/27/2002	EP1259499A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
11/27/2002	EP1259488A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors
11/27/2002	EP1259292A2 Therapeutic agents
11/27/2002	EP1259260A1 Combination therapy for the treatment of inflammatory and respiratory diseases
11/27/2002	EP1259259A2 Mucosal adjuvant formulation
11/27/2002	EP1259247A1 DNA ENCODING HUMAN ACID-SENSING ION CHANNEL BNaC4 (ASIC4)
11/27/2002	EP1259236A1 Tyrosine kinase inhibitors
11/27/2002	EP1259235A1 Tyrosine kinase inhibitors
11/27/2002	EP1259234A1 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
11/27/2002	EP1259233A1 Modulation of bone formation
11/27/2002	EP1259125A1 Inulin products with improved nutritional properties
11/27/2002	EP1259120A2 Method for isolating sponge collagen and producing nanoparticulate collagen, and the use thereof
11/27/2002	EP1089742B1 Composition for the prevention and/or treatment of osteoporosis and alterations due to menopause syndrome, comprising propionyl-l-carnitine and genistein
11/27/2002	EP1000035B1 Substituted 6-phenylphenanthridines
11/27/2002	EP0920330B1 hCG AND DERIVATIVES AS MATRIX METALLOPROTEASES INHIBITORS
11/27/2002	EP0777471B1 Inhibition of leukotriene biosynthesis with urea derivatives
11/27/2002	EP0708648B1 Inhibition of nitric oxide production by retinoic acid
11/27/2002	CN1382211A Treatment of inflammatory or malignant disease using dnazymes
11/27/2002	CN1382151A Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl)-1h-indol-5-ols
11/27/2002	CN1382146A Imidazole derivatives asphosphodiesterase VII inhibitors
11/27/2002	CN1382144A Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
11/27/2002	CN1382143A Inhibitors of alpha L beta 2 mediated cell adhesion
11/27/2002	CN1382142A Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
11/27/2002	CN1382136A N-heterocyclic derivatives as NOS inhibitors
11/27/2002	CN1382122A Pyrrole derivatives as phosphodiesterase VII inhibitors
11/27/2002	CN1382121A C16 unsaturated FP-selective prostaglandins analogs
11/27/2002	CN1382118A Biocyclic amino acids aspharmaceutical agents
11/27/2002	CN1382058A Method to enhance healing of sternum after sternotomy
11/27/2002	CN1382053A Novel hormonal composition and use thereof
11/27/2002	CN1382043A Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials
11/27/2002	CN1382037A Oral solution containing galanthamine and sweetening agent
11/27/2002	CN1382036A Solubilized pharmaceutical composition for parenteral administration
11/27/2002	CN1381269A Plaster for treating inflammations and sores
11/27/2002	CN1381243A Medicine for treating hyperosteogeny and its preparing process
11/26/2002	US6486186 Thiazole compounds as cyclic AMP-specific phosphodiesterase inhibitors and method of using the same
11/26/2002	US6486122 Methods of increasing body weight in a subject by administering TGF-α
11/26/2002	US6485755 Methods of using electron active compounds for managing cancer
11/26/2002	CA2258285C Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
11/21/2002	WO2002092781A2 Peptide compounds for counteracting reactive oxygen species and free radicals

1 ... 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 ... 820